#Glycovax
LightNews LightNews
newsen.bsky.social
Glycovax Pharma Launches Affordable CRM197 Protein for Vaccines#Canada#Montreal#Glycovax_Pharma#CRM197#Espoir_Therapeutics
Glycovax Pharma Launches Affordable CRM197 Protein for Vaccines
Glycovax Pharma Inc. begins biomanufacturing of CRM197 protein, aiming to enhance vaccine accessibility for human and animal use.
third-news.com
June 9, 2025 at 1:35 PM
newsen.bsky.social
Glycovax Pharma Announces Strategic Appointments to Fuel Growth and Innovation in Biotechnology#Canada#Montreal#Glycovax_Pharma#Cédric_Héroux#Thierry_Cyr-Lafleur
Glycovax Pharma Announces Strategic Appointments to Fuel Growth and Innovation in Biotechnology
Glycovax Pharma has appointed Cédric Héroux and Thierry Cyr-Lafleur to accelerate operations and commercial development, enhancing its biotechnological prowess.
third-news.com
September 15, 2026 at 1:25 PM
courrierlaval.com
Glycovax Pharma entreprend la bioproduction à grande échelle de deux composants vaccinaux
Glycovax Pharma entreprend la bioproduction à grande échelle de deux composants vaccinaux
Le vent souffle fort dans les voiles de l’entreprise incubée au Centre québécois d'innovation en biotechnologie (CQIB), Glycovax Pharma.
courrierlaval.com
July 15, 2025 at 9:02 PM
newsen.bsky.social
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma partners with NRC and Université de Montréal to create a groundbreaking vaccine for Pseudomonas aeruginosa infections, supported by Quebec funding.
third-news.com
October 8, 2025 at 1:47 PM
newsen.bsky.social
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma has received approval from the National Research Council of Canada to further develop a vaccine targeting deadly Pseudomonas aeruginosa infections.
third-news.com
August 18, 2025 at 1:52 PM
newsen.bsky.social
Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines#Canada#Montreal#Vaccine_Development#Glycovax#SLA_Adjuvant
Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines
Glycovax Pharma has announced the large-scale production of sulfated lactosyl archaeol (SLA) adjuvant, enhancing vaccine efficacy globally.
third-news.com
July 8, 2025 at 2:06 PM
l2plabs.bsky.social
Université Laval and Glycovax Pharma Enter into an Exclusive Global License Agreement for the Development of Innovative Galectin-3 Inhibitors
MONTRÉAL and QUÉBEC CITY, April 22, 2026 /PRNewswire/ - Université Laval and Glycovax Pharma announce an exclusive global license agreement granting Glycovax the rights to develop and commercialize a family of compounds targeting galectin-3, a cellular protein involved in multiple...
dlvr.it
April 22, 2026 at 1:02 PM
l2plabs.bsky.social
Glycovax Pharma, the National Research Council of Canada and the Université de Montréal, join forces to develop an innovative vaccine against the bacterium Pseudomonas aeruginosa (Pa), made possible through CQDM's financial support
Fighting respiratory diseases, particularly in hospitals MONTRÉAL, Oct. 8, 2025 /PRNewswire/ - Glycovax Pharma today announced a strategic collaboration with the National Research Council of Canada (NRC) and the Faculty of Veterinary Medicine at the Université de Montréal to develop a...
dlvr.it
October 8, 2025 at 1:03 PM
l2plabs.bsky.social
Glycovax Pharma is granted a licence by the National Research Council of Canada to develop a vaccine to fight nosocomial disease related to Pseudomonas aeruginosa (Pa) infections
MONTREAL, Aug. 18, 2025 /PRNewswire/ - Pseudomonas aeruginosa (Pa) is a bacterium responsible for nosocomial infections and is often fatal when contracted by people living with cystic fibrosis. There is currently no vaccine to prevent Pa-related infections even though this bacterium is a...
dlvr.it
August 18, 2025 at 1:03 PM
l2plabs.bsky.social
Glycovax Pharma commercializes a more affordable CRM197 protein
MONTREAL, June 9, 2025 /PRNewswire/ - Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient...
dlvr.it
June 9, 2025 at 1:03 PM